🚀 Medial Secures Investment on Shark Tank India - Fueling the Future of Professional Social Networking. 🔥
✕
Login
Home
News
Messages
Startup Showcase
Trackers
Premium
Premium Content
Jobs
Notifications
Settings
Try our Valuation Calculator →
Log In
News on Medial
What’s the game plan of life sciences VC fund floated by Actis-owned firm's execs?
VCCircle
·
8m ago
Medial
Three executives from Rx Propellant, a life sciences infrastructure provider owned by Actis, have launched a venture capital fund to invest in biotech startups. Vishal Goel and Jasmeet Chhabra, with a background in real estate investments, have joined forces with a former RX Proellant executive to form the new fund. The focus of the fund will be on supporting innovation in the biotech sector.
View Source
Related News
Israeli VC firm Peregrine Ventures mulls new early-stage fund
VCCircle
·
7m ago
Medial
Peregrine Ventures, an Israeli VC firm managing $600 million in assets, is contemplating a new early-stage fund launch later this year. Based in Tel Aviv, the firm has invested in at least 57 healthcare and life sciences companies.
View Source
Kotak Alternate Asset raising third life sciences-focused PE fund
VCCircle
·
1y ago
Medial
Kotak Alternate Asset Managers Ltd is raising capital for its third healthcare and life sciences-focused private equity fund. This comes after nearly seven years since the launch of its previous fund. Kotak Alternate is the alternative asset management arm of Kotak Mahindra Group. The fund aims to invest in healthcare and life sciences companies in India.
View Source
Kotak Alternate Asset hits first close of third life sciences-focused PE fund
VCCircle
·
7m ago
Medial
Kotak Alternate Asset Managers Ltd, part of Kotak Mahindra Group, announced the first close of its third life sciences-focused private equity fund, raising Rs 250 crore from family offices, UHNWIs, veterans, and institutions. The fund targets Rs 1,600 crore for investments in early- to growth-stage companies in life sciences, including pharma, biotech, and medical devices. Established in 2005, Kotak Alternate Asset manages over $22 billion across various asset classes.
View Source
Sixth Street-Backed Caris Life Sciences Targets $423.5 Million IPO With $5.35 Billion Valuation in Oncology Precision Medicine | DeepNewz VC
deepnewz
·
2m ago
Medial
Caris Life Sciences, supported by Sixth Street, aims to raise $423.5 million through an initial public offering (IPO), valuing the company at approximately $5.35 billion. As a biotech firm, Caris Life Sciences specializes in innovative medical technologies and diagnostics, seeking to capitalize on public market opportunities. This IPO reflects a growing interest and investment in the medtech sector, driving advancements and potential through substantial capital inflow for research and development.
View Source
Quadria, TPG eye up to 25% stake for $100 mn in Samarth Life Sciences
Livemint
·
10m ago
Medial
Private equity investors, including Quadria Capital and TPG Capital, are considering investing around $100 million for a 20-25% stake in Samarth Life Sciences. The Mumbai-based critical care drugs provider is wholly-owned by its promoter group and this would be its first external investment. The potential deal is expected to be a secondary transaction, with existing shareholders selling their stakes. Samarth Life Sciences develops and manufactures life-saving critical care and other drugs, with plans to expand and collaborate globally. India's pharmaceutical and healthcare sectors have seen increased deal activity due to the diversification of global supply chains.
View Source
IXP unveils Rs 200 Cr early-stage fund for lifesciences startups
Entrackr
·
6m ago
Medial
IXP, a Life Sciences VC backed by JV Ventures, has announced the launch of its first fund to invest in early-stage companies. The fund aims to build a portfolio of B2B companies ranging from pre-seed to Series A stages. The IXP Lifesciences Catalyst Fund is targeting a corpus of Rs 200 crore, with a greenshoe option of Rs 100 crore. The fund plans to create a portfolio of 20-25 companies addressing gaps in the market for both services and products. Within the Life Sciences sector, the fund will invest in innovations across areas such as pharma, biotechnology, medical technology, specialty chemicals, agrotechnology, and nutraceuticals. Through IXP Venture Studio, it will co-create companies alongside scientists to develop ideas that address unmet market needs. Unlike traditional VCs, it takes a hands-on approach, actively participating from concept to scale. The Venturepreneur Program has been designed to transform scientists into founders. According to IXP, early-stage companies require access to larger ecosystems, including laboratories, networks, and R&D services, which it provides through PoweRx, the Life Sciences vertical of JV Ventures. The VC firm leverages synergies within the group to create a winning proposition for portfolio companies. IXP (Innovation Acceleration Platform) aims to support scientists and innovators in their entrepreneurial journey by integrating them into a rich life sciences ecosystem. The VC firm emphasizes that it is built by a strong team and understands the capital-intensive nature and long gestation periods associated with R&D, helping bring innovative ideas to market.
View Source
Inside Avendus’ strategy to tap India’s next wave of unicorns
Livemint
·
23d ago
Medial
Avendus Future Leaders Fund (FLF) has invested ₹300 crore in Aragen Life Sciences alongside SBI Life Insurance, each contributing ₹150 crore. This marks FLF’s second healthcare investment this year, following a previous stake in La Renon Healthcare. The investment was made from FLF III, reflecting the fund's ongoing interest and commitment to the healthcare sector.
View Source
Actis raises $1.7 bn for infra fund, explores more opportunities in India
VCCircle
·
3m ago
Medial
Actis, a private equity firm, has raised $1.7 billion for its second Long Life Infrastructure Fund, focusing on sustainable infrastructure in emerging markets like India. The fund has deployed nearly half its capital, significantly in Indian assets, and is exploring more opportunities in the renewable energy and digital infrastructure sectors. Actis’s strategy prioritizes stable, long-term income and aligns with India's energy demand and clean energy targets, emphasizing infrastructure's scale and resilience.
View Source
Avendus Fund leads Rs 300 Cr investment in Aragen Life Sciences
YourStory
·
23d ago
Medial
Avendus Future Leaders Fund III led a Rs 300 crore investment in Aragen Life Sciences, a major Indian CRDMO. Partnered with SBI Life Insurance, the fund acquired a minority stake. Avendus's second investment, following La Renon Healthcare, highlights confidence in India's growing CRDMO sector amid increased global outsourcing. Aragen, backed by investors like Goldman Sachs, aims to enhance its services for global pharma innovations with this funding, strengthening its market position further.
View Source
Former Venture Garage, Cuemath execs float climate-focused VC fund
VCCircle
·
10m ago
Medial
Former partner of Venture Garage, Pawan Raj Kumar, and ex-VP of Cuemath, Aakash Kushwaha, have launched a new venture capital fund called ZeCa Ventures. The fund, based in Bengaluru, will focus on investing in startups and companies that are dedicated to reducing carbon footprint and addressing climate change. The aim is to support innovative solutions that contribute to a more sustainable future.
View Source
Trackers
Active Indian VC’s
OG Capital
Email
With a hands-on approach, OG Capital aims to invest in over 20 promising...
Accel Partners
Email
Early and growth-stage investments in disruptive technology companies with...
Blume
Email
Early-stage venture capital firm investing in technology startups in India. Focus on...
Access All Trackers
Startup Showcase Winners
Aug 2025
Jurifly
Build. Comply. Fund. Fly.
FloatFi App
Crypto to INR payments app for Indians
ForkMyCV
Your CV, Done Right.
Enter Ongoing Startup Showcase
Top Users
Trending News on Medial
Download the medial app to read full posts, comements and news.
Go to Medial App
Not Now
Know everything that’s happening in the startup ecosystem, first.
Enable Notifications?
No, thanks
Count me in
